• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Exagen Inc.

    4/27/26 5:18:12 PM ET
    $XGN
    Medical Specialities
    Health Care
    Get the next $XGN alert in real time by email
    DEFA14A 1 a2026defa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )
    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material under §240.14a-12
    Exagen Inc.
    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):
    ☒No fee required.
    ☐Fee paid previously with preliminary materials.
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.






    exagen26amnoticedraft5_pag.jpg




    exagen26amnoticedraft5_paga.jpg


    Get the next $XGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XGN

    DatePrice TargetRatingAnalyst
    9/11/2025$15.00Buy
    B. Riley Securities
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    7/23/2025$12.00Buy
    Craig Hallum
    8/5/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    11/11/2021$33.00 → $30.00Overweight
    Keybanc
    10/15/2021$26.00Outperform
    Cowen
    More analyst ratings

    $XGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Mckhann Chas

    3/A - EXAGEN INC. (0001274737) (Issuer)

    4/21/26 8:00:11 PM ET
    $XGN
    Medical Specialities
    Health Care

    New insider Mckhann Chas claimed ownership of 7,500 units of Restricted Stock Units (SEC Form 3)

    3 - EXAGEN INC. (0001274737) (Issuer)

    3/16/26 9:16:06 PM ET
    $XGN
    Medical Specialities
    Health Care

    Chief Financial Officer Black Jeffrey G. was granted 76,511 shares, increasing direct ownership by 29% to 343,953 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    3/16/26 7:17:29 PM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

    Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the publication of a new systematic review demonstrating that the AVISE Lupus algorithm delivers markedly superior diagnostic accuracy and consistency across patient populations compared with conve

    6/1/26 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. Reports First Quarter 2026 Results

    CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.   Three Months Ended March 31,   2026  2025Unaudited. In thousands, except ASP data.  Revenue $17,306  $15,498 Gross margin  59.0%  58.9%Operating expenses $13,619  $12,488 Operating loss $(3,414) $(3,365)Net loss $(3,967) $(3,752)Adjusted EBITDA $(2,160) $(2,508)Trailing-twelve-month average selling price (ASP) $444  $419 Cash and cash equivalents $21,513  $11,194           First Quarter 2026 Highlights: Achieved record total revenue of $17.3 million, an increas

    5/11/26 8:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

    CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company's results. Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen Investor Relations website at investors.exagen.com Replay: A telephone replay will be available until Monday, May 25, 2026

    4/27/26 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Exagen with a new price target

    B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00

    9/11/25 8:42:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Exagen from Sector Weight to Overweight and set a new price target of $12.00

    7/30/25 7:17:58 AM ET
    $XGN
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Exagen with a new price target

    Craig Hallum initiated coverage of Exagen with a rating of Buy and set a new price target of $12.00

    7/23/25 7:55:19 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    SEC Filings

    View All

    SEC Form S-8 filed by Exagen Inc.

    S-8 - EXAGEN INC. (0001274737) (Filer)

    5/12/26 4:03:23 PM ET
    $XGN
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Exagen Inc.

    10-Q - EXAGEN INC. (0001274737) (Filer)

    5/11/26 9:17:12 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EXAGEN INC. (0001274737) (Filer)

    5/11/26 8:03:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/19/24 7:24:38 PM ET
    $XGN
    Medical Specialities
    Health Care

    President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/18/24 6:32:33 PM ET
    $XGN
    Medical Specialities
    Health Care

    Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    5/16/24 8:02:50 PM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Leadership Updates

    Live Leadership Updates

    View All

    Exagen Inc. Appoints Chas McKhann to Board of Directors

    CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

    7/17/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

    CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea

    6/23/25 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

    CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci

    8/1/24 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    2/14/24 2:42:55 PM ET
    $XGN
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    2/14/24 7:12:55 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Financials

    Live finance-specific insights

    View All

    Exagen Inc. Reports First Quarter 2026 Results

    CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.   Three Months Ended March 31,   2026  2025Unaudited. In thousands, except ASP data.  Revenue $17,306  $15,498 Gross margin  59.0%  58.9%Operating expenses $13,619  $12,488 Operating loss $(3,414) $(3,365)Net loss $(3,967) $(3,752)Adjusted EBITDA $(2,160) $(2,508)Trailing-twelve-month average selling price (ASP) $444  $419 Cash and cash equivalents $21,513  $11,194           First Quarter 2026 Highlights: Achieved record total revenue of $17.3 million, an increas

    5/11/26 8:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

    CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company's results. Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen Investor Relations website at investors.exagen.com Replay: A telephone replay will be available until Monday, May 25, 2026

    4/27/26 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen investor relations website at investors.exagen.com Replay: A telephone replay will be available until Tuesday, March 24, 2026: U.

    2/24/26 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care